KRAS and colorectal carcinoma: Another ongoing trial of interest includes NCT05722327, which is a phase I effort aiming to study the combination of adagrasib, cetuximab, and irinotecan in KRAS G12C CRC treated with two previous lines of therapy (NCT05722327).